Upper Airway Research Laboratory (URL), Ghent University Hospital, Ghent, Belgium.
J Allergy Clin Immunol. 2012 Aug;130(2):376-81.e8. doi: 10.1016/j.jaci.2012.05.012. Epub 2012 Jun 26.
The role of IgE in patients with severe asthma is not fully understood.
We sought to investigate whether IgE to Staphylococcus aureus enterotoxins might be relevant to disease severity in adult asthmatic patients.
Specific IgE antibody concentrations in serum against enterotoxins, grass pollen (GP), and house dust mite allergens and total IgE levels were measured in adult cohorts of 69 control subjects, 152 patients with nonsevere asthma, and 166 patients with severe asthma. Severe asthma was defined as inadequately controlled disease despite high-dose inhaled corticosteroids plus at least 2 other controller therapies, including oral steroids.
Enterotoxin IgE positivity was significantly greater in patients with severe asthma (59.6%) than in healthy control subjects (13%, P< .001). Twenty-one percent of patients with severe asthma with enterotoxin IgE were considered nonatopic. Logistic regression analyses demonstrated significantly increased risks for enterotoxin IgE-positive subjects to have any asthma (OR, 7.25; 95% CI, 2.7-19.1) or severe asthma (OR, 11.09; 95% CI, 4.1-29.6) versus enterotoxin IgE-negative subjects. The presence of GP or house dust mite IgE antibodies was not associated with either significantly increased risk for asthma or severity. Oral steroid use and hospitalizations were significantly increased in patients with enterotoxin IgE and nonatopic asthma. GP IgE was associated with a higher FEV(1) percent predicted value, and enterotoxin IgE was associated with a lower FEV(1) percent predicted value.
Staphylococcal enterotoxin IgE antibodies, but not IgE against inhalant allergens, are risk factors for asthma severity. We hypothesize that the presence of enterotoxin IgE in serum indicates the involvement of staphylococcal superantigens in the pathophysiology of patients with severe asthma.
IgE 在重度哮喘患者中的作用尚未完全阐明。
我们旨在研究金黄色葡萄球菌肠毒素的 IgE 是否与成年哮喘患者的疾病严重程度相关。
我们测量了 69 名健康对照者、152 名非重症哮喘患者和 166 名重症哮喘患者血清中针对肠毒素、草花粉(GP)和屋尘螨变应原的特异性 IgE 抗体浓度和总 IgE 水平。重症哮喘定义为尽管使用高剂量吸入性皮质激素和至少 2 种其他控制药物(包括口服皮质激素),疾病仍未得到充分控制。
重症哮喘患者肠毒素 IgE 阳性率(59.6%)明显高于健康对照组(13%,P<.001)。21%的重症哮喘患者肠毒素 IgE 阳性者被认为是非特应性的。Logistic 回归分析显示,肠毒素 IgE 阳性患者发生任何哮喘(OR,7.25;95%CI,2.7-19.1)或重度哮喘(OR,11.09;95%CI,4.1-29.6)的风险显著增加,与肠毒素 IgE 阴性患者相比。GP 或屋尘螨 IgE 抗体的存在与哮喘或严重程度的风险增加均无显著相关性。肠毒素 IgE 阳性和非特应性哮喘患者口服皮质激素的使用率和住院率显著增加。GP IgE 与更高的 FEV1%预计值相关,而肠毒素 IgE 与更低的 FEV1%预计值相关。
金黄色葡萄球菌肠毒素 IgE 抗体而不是吸入性变应原的 IgE 是哮喘严重程度的危险因素。我们假设血清中肠毒素 IgE 的存在表明金黄色葡萄球菌超抗原参与了重症哮喘患者的病理生理学过程。